Compare LTC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTC | AGIO |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1994 | 2013 |
| Metric | LTC | AGIO |
|---|---|---|
| Price | $36.19 | $33.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $40.00 | $38.88 |
| AVG Volume (30 Days) | 470.8K | ★ 896.9K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.96% | N/A |
| EPS Growth | ★ 23.53 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $262,854,000.00 | $43,011,000.00 |
| Revenue This Year | N/A | $76.75 |
| Revenue Next Year | N/A | $170.73 |
| P/E Ratio | $76.83 | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $33.64 | $22.24 |
| 52 Week High | $40.80 | $46.00 |
| Indicator | LTC | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 67.71 |
| Support Level | $35.52 | $32.47 |
| Resistance Level | $37.00 | $36.07 |
| Average True Range (ATR) | 0.91 | 1.58 |
| MACD | 0.04 | 0.54 |
| Stochastic Oscillator | 45.30 | 90.86 |
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.